Reuters logo
BRIEF-Mitsubishi Tanabe Pharma Corp says RADICAVA to treat ALS will cost $1086 per infusion
May 5, 2017 / 9:07 PM / 7 months ago

BRIEF-Mitsubishi Tanabe Pharma Corp says RADICAVA to treat ALS will cost $1086 per infusion

May 5 (Reuters) - Mitsubishi Tanabe Pharma Corp:

* Mitsubishi Tanabe Pharma Corp says will offer co-pay assistance for commercially insured patients to help reduce their out-of-pocket costs

* Mitsubishi Tanabe Pharma corp says RADICAVA to treat patients with als will cost $1,086 per infusion, $11,194 per dosage cycle

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below